National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 65696 [2023-20695]
Download as PDF
<![CDATA[
65696
Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices
20852, (240) 747–7530, mairi.noverr@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 19, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20656 Filed 9–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Population Assessment of Tobacco and
Health (PATH) Study.
Date: October 31, 2023.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Shareen Iqbal, Ph.D.,
M.P.H., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
K Alternate SEP.
Date: November 3, 2023.
Time: 12:00 p.m. to 1:45 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marisa Srivareerat, Ph.D.,
Scientific Review Officer, Scientific Review
VerDate Sep<11>2014
20:11 Sep 22, 2023
Jkt 259001
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 435–1258,
marisa.srivareerat@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Animal Genomics and Functional
Validation/Characterization of Genes/
Variants in SUD.
Date: November 27, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20693 Filed 9–22–23; 8:45 am]
BILLING CODE 4140–01–P
Pandemic Preparedness (ReVAMPP) Centers
for Flaviviridae and Togaviridae (U19
Clinical Trial Not Allowed).
Date: October 24–25, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F30, Rockville, MD
20852, (240) 669–5931, jakesse@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20695 Filed 9–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information on the DRAFT
Scientific Integrity Policy of the
National Institutes of Health
AGENCY:
National Institutes of Health,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Research and Development
of Vaccines and Monoclonal Antibodies for
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
ACTION:
Request for information.
The National Institutes of
Health (NIH) is soliciting comments and
suggestions from the public on the
DRAFT ‘‘Scientific Integrity Policy of
the National Institutes of Health’’
(DRAFT NIH Scientific Integrity Policy).
The DRAFT NIH Scientific Integrity
Policy codifies NIH’s long-standing
expectations to preserve scientific
integrity throughout all NIH activities,
establishes key roles and
responsibilities for those who will lead
the agency’s scientific integrity program,
and, as appropriate, establishes relevant
reporting and evaluation mechanisms.
DATES: The DRAFT ‘‘Scientific Integrity
Policy of the National Institutes of
Health’’ is open for public comment for
a period of 45 days. To ensure
consideration, comments must be
submitted in writing by November 9,
2023.
ADDRESSES: Comments may be
submitted electronically at https://
osp.od.nih.gov/comment-form-draftscientific-integrity-policy-for-thenational-institutes-of-health/.
SUMMARY:
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 88, Number 184 (Monday, September 25, 2023)]
[Notices]
[Page 65696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20695]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Research and Development of
Vaccines and Monoclonal Antibodies for Pandemic Preparedness
(ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical
Trial Not Allowed).
Date: October 24-25, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Scott Jakes, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3F30, Rockville, MD
20852, (240) 669-5931, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20695 Filed 9-22-23; 8:45 am]
BILLING CODE 4140-01-P
